Behjatolah Monzavi‐Karbassi

Federal Grant PI High Impact

Associate Professor

UAMS

Last publication 2024 Last refreshed 2026-05-09

faculty

karbassi@uams.edu

24 h-index 78 pubs 1,607 cited

Research Areas

Links

ORCID Research Group

OverviewAI-generated summary

Behjatolah Monzavi‐Karbassi's research focuses on understanding and manipulating immune responses, particularly in the context of cancer and other diseases. His work investigates the potential of vaccines, such as the P10s-PADRE vaccine, to elicit both humoral and cellular immune responses in patients undergoing treatment for conditions like ER-positive breast cancer. This includes assessing vaccine-mediated cellular immune responses in patients receiving combined vaccine and chemotherapy, and characterizing peripheral immune correlates of tumor response.

Further research explores the interactions within the tumor microenvironment, including the role of tumor exosomes and macrophages, with a specific focus on tumor-associated glycans and scavenger receptor class A. Monzavi‐Karbassi also examines the impact of dietary components, such as soy protein concentrates and isoflavones, on serum inflammatory protein levels in animal models. His laboratory is involved in identifying and characterizing antibodies to tumor-associated antigens, including antibodies to chondroitin sulfate proteoglycan 4 (CSPG4) that react with tumor-associated carbohydrate antigens. He has secured federal funding from the NIH/National Cancer Institute for research targeting SR-A as a therapeutic strategy in breast cancer.

Metrics

h-index: 24
Publications: 78
Citations: 1,607

Selected Publications

Abstract PO5-02-05: Assessing Vaccine-Mediated Cellular Immune Responses in Patients Receiving Combined Vaccine and Chemotherapy Treatment (2024)

DOI OpenAlex
Abstract 3860: Characterizing peripheral immune correlates of tumor response in breast cancer patients immunized with the P10s-PADRE vaccine (2024)

DOI OpenAlex
Abstract 186: Tumor exosome-macrophage interactions: The role of tumor-associated glycans and scavenger receptor class A (2024)

DOI OpenAlex
The Tumor Microenvironment and Immune Response in Breast Cancer (2024)

2 citations DOI OpenAlex
Abstract 700: Induction of cancer-specific T-cell responses in patients immunized with P10s-PADRE vaccine (2023)

DOI OpenAlex
Feeding Soy Protein Concentrates with Low and High Isoflavones Alters 9 and 18 Weeks Serum Isoflavones and Inflammatory Protein Levels in Lean and Obese Zucker Rats (2023)

9 citations DOI OpenAlex
VT68.2: An Antibody to Chondroitin Sulfate Proteoglycan 4 (CSPG4) Displays Reactivity against a Tumor-Associated Carbohydrate Antigen (2023)

3 citations DOI OpenAlex
Feeding Obese Zucker Rats With Soy Protein Concentrate With High Isoflavones Compared to Low Isoflavones Leads to a Significant Reduction of Serum Tumor Necrosis Factor-α (2022)

DOI OpenAlex
Abstract P2-14-15: Timing of the immunization defines immune signature of a peptide cancer vaccine combined with Neoadjuvant chemotherapy in HR+ breast cancer patients (2022)

DOI OpenAlex
P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses (2021)

10 citations DOI OpenAlex